This is an aggregated industry headline. Read the full story at BioPharma Dive →
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.
By BioPharma Dive
· Jul 1, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
AstraZeneca has impressed oncology patient groups, rising to second place on PatientView's corporate reputatio…
The WeekFierceBiotech ↗
Insilico Medicine has signed a deal worth up to $600 million with Japanese Big Pharma Takeda to collaborate on…
The WeekBriefing
Tzield gains accelerated approval to delay insulin decline in children 8–17 with recently diagnosed Stage 3 ty…